<DOC>
	<DOCNO>NCT02989753</DOCNO>
	<brief_summary>This study design pilot study order estimate effect VAL070-A VAL070-B product variability LDL cholesterol lipid metabolism since data still unknown product specific population . Collected data provide reliable information may use plan subsequent large main study .</brief_summary>
	<brief_title>Effects Two Herbal Dietary Supplements Lipid Metabolism Moderate Hypercholesterolemia Hypertriglyceridemia</brief_title>
	<detailed_description>Main objective The primary objective present trial ass beneficial effect VAL070-B compare placebo , blood LDL cholesterol level moderate hypercholesterolemic hypertriglyceridemic subject 12 week consumption . Secondary objective Secondary objective study assess effect VAL070-A VAL070-B , compare placebo , moderate hypercholesterolemic hypertriglyceridemic subject 12 week consumption follow parameter : - Blood level LDL cholesterol ( VAL070-A compare placebo VAL070-A compare VAL070-B ) , - Lipid profile : Blood level triglyceride , total cholesterol , HDL-cholesterol non- HDL cholesterol , - Glycaemia , - Blood hsCRP , - Fructosamine , - Blood total free fatty acid level , - Anthropometrics assess body weight ( BW ) , waist circumference ( WC ) , hip circumference ( HC ) waist hip ratio ( WHR ) . Safety objectives The following parameter , analyze baseline 12 week consumption , participate safety objective : - Blood level urea creatinine , - Blood level GGT , AST ALT , - Complete blood count , - Hemodynamic measurement : heart rate ( HR ) , systolic blood pressure ( SBP ) diastolic blood pressure ( DBP ) , - Adverse event .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Age 18 70 year ( limit include ) , BMI 18.5 40 kg/m2 ( limit include ) , For woman : Non menopausal reliable contraception since least 3 cycle begin study agree keep entire duration study ( condom spermicide gel estrogen/progestin combination contraception accept ) menopausal without hormone replacement therapy ( estrogenic replacement therapy begin less 3 month exclude ) , Weight stable within ± 5 % last three month , Non smoke tobacco consumption &lt; 20 cigarette / day , Good general mental health opinion investigator : clinically significant relevant abnormality medical history physical examination , Able willing participate study comply protocol procedure evidence dated sign informed consent form , Affiliated social security scheme , Agree register volunteer biomedical research file . After V1 biological analysis subject eligible study follow criterion : Fasting blood LDLc level ( use Friedewald estimation method ) 1.3 2.2 g/L ( limit include ± 2 % tolerate around ) , Fasting blood triglyceride level &gt; 1.5 g/L , Blood TSH level 0.27 4.2 μIU/mL ( limit include ) . Within 3 month follow exit study failure comply one inclusion criterion list , rescreening could perform . Suffering metabolic disorder diabetes , uncontrolled thyroidal trouble metabolic disorder , Suffering severe chronic disease ( e.g . cancer , HIV , renal failure , hepatic biliary disorder ongoing , chronic inflammatory digestive disease , arthritis chronic respiratory trouble , etc . ) gastrointestinal disorder find inconsistent conduct study investigator ( e.g . celiac disease ) , With history ischemic cardiovascular event , Having undergone recent surgical procedure ( le 6 month ) , Suffering uncontrolled hypertension ( systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg ) , With know suspect food allergy intolerance hypersensitivity study product ' ingredient , Pregnant lactate woman intend become pregnant within 3 month ahead , For woman : pregnancy breastfeed finish since less 6 month , Under cholesterol and/or lipidlowering treatment ( e.g . statin , fibrates , ezetimibe , bile acid sequestrants , niacin , etc . ) stop less 3 month V1 visit , Requiring cholesterol lower immediate pharmacologic intervention accord current recommendation ( AFSSAPS , 2005 ) , Under medication could affect blood lipid parameter ( e.g . longterm corticosteroid systemic drug , systemic antibody , androgen enzyme inducer , etc . ) stop less 3 month randomization ( antihypertensive stable longterm treatment tolerate ) , Regular intake dietary supplement `` functional food '' know impact lipid metabolism ( e.g . rich plant stanol sterol like PROACTIV DANACOL product , red yeast rice , policosanol , capsule contain omega3 fatty acid fish oil , contain beta glucanes , konjac extract cinnamon , etc . ) stop less 3 month V1 visit , Under treatment dietary supplement could significantly affect parameter ( ) follow study accord investigator stop short period V1 visit , With significant change food habit physical activity 3 month V1 visit agree keep unchanged throughout study , With current plan next 3 month specific diet ( hyper hypocaloric , vegan , vegetarian ... ) stop less 3 month study , With personal history anorexia nervosa , bulimia significant eating disorder accord investigator , Consuming 3 standard drink alcoholic beverage daily men 2 daily woman agree keep alcohol consumption habit unchanged throughout study , Having lifestyle deem incompatible study accord investigator include high level physical activity ( define 10 hour significant physical activity week , walk exclude ) , Who make blood donation 3 month V1 visit intend make within 3 month ahead , Taking part another clinical trial exclusion period previous clinical trial , Having receive , last 12 month , indemnity clinical trial high equal 4500 Euros , Under legal protection ( guardianship , wardship ) deprive right follow administrative judicial decision , Presenting psychological linguistic incapability sign inform consent , Impossible contact case emergency , After V1 biological analysis subject consider non eligible study follow criterion : Fasting blood triglyceride &gt; 4 g/L , Fasting glycaemia &gt; 1.26 g/L Blood AST , ALT GGT &gt; 3xULN ( Upper Limit Normal ) , Blood urea &gt; 12.11 mmol/L ( value correspond 1.5xULN ) creatinine &gt; 125 μmol/L , Blood hsCRP &gt; 10 mg/L , Complete blood count clinically significant abnormality accord investigator . Within 3 month follow exit study failure comply one exclusion criterion list , rescreening could perform .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prevention</keyword>
</DOC>